

2022 Joint Pre-ECTRIMS workshop

25 October 2022
Amsterdam, The Netherlands

A Continuing Medical Education Programme provided by



European
Charcot
Foundation



and endorsed by **ECTRIMS**
EUROPEAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS

Overview

The field of Multiple Sclerosis (MS) is continuously evolving following the discovery of new pathogenetic mechanisms and new treatment targets. New evidence on MS epidemiology have renovated the interest in viral infections, in particular by Epstein-Barr virus, as main triggers of autoimmune attack to the central nervous system, opening the way for innovative treatment approaches. Recently, new drugs have been licensed for progressive forms of MS, highlighting the need for a more accurate classification of these forms and a better understanding of the mechanisms underpinning disability progression.

The Pre-ECTRIMS workshop, stemming from a collaboration between the Med-Ex Learning & EXCEMED Group, the European Charcot Foundation and AcademicCME, aims to provide a yearly update on the main novelties in the most debated themes in the field of MS, through frontal lectures and open discussions involving experts from all over the world.

Learning objectives

- Describe new immunological mechanisms underpinning MS
- Illustrate mechanisms of action and safety profile of new MS treatments
- Describe emerging environmental factors influencing MS development
- Discuss how to identify and monitor disability progression

Scientific Organizers

Giancarlo Comi

Vita-Salute San Raffaele
Milan, Italy

F.D. Lublin

The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, USA

Accreditation

The 2022 joint pre-ECTRIMS workshop, Amsterdam, Netherlands, 25/10/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity."

"Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

"Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



Organizing Secretariat

Med-Ex Learning-EXCEMED Group

alessia.addressi@medexlearning.com

mattia.pascucci@medexlearning.com

AcademicCME

cbenedek@academiccme.com

nmcmenamin@academiccme.com

Venue

Van Der Valk Zuidas hotel

Tommaso Albinonistraat 200. 1083HM

Amsterdam, The Netherlands

FACULTY



Francesca Aloisi

Department of Neuroscience
Istituto Superiore di Sanità
Rome, Italy

Alberto Ascherio

Department of Epidemiology and Nutrition
Harvard T.H. Chan School of Public Health
Boston, USA

Amit Bar-Or

Multiple Sclerosis Division
Department of Neurology
Perelman School of Medicine
and
Center for Neuroinflammation and Neurotherapeutics
Children's Hospital of Pennsylvania
Philadelphia, USA

Giancarlo Comi


Vita-Salute San Raffaele
Milan, Italy

Benjamin M. Greenberg

Department of Neurology and Neurotherapeutics
UT Southwestern Medical Center
Dallas, USA

Hans Peter Hartung

Center for Neuropsychiatry
Department of Neurology
Heinrich-Heine-University Dusseldorf
Dusseldorf, Germany



Matilde Inglese

Neurology Imaging
Icahn School of Medicine at Mount Sinai
New York, USA

Ludwig Kappos

Department of Biomedicine
University Hospital Basel
Basel, Switzerland

Stephen Krieger

The Corinne Goldsmith Dickinson Centre for MS at Mount Sinai
New York, USA

Hans Lassmann

Division of Neuroimmunology
Center for Brain Research
Medical University of Wien
Wien, Austria

Letizia Leocani

Institute of Experimental Neurology
University Vita-Salute IRCCS
Milan, Italy

Fred D. Lublin

Saunders Family Professor of Neurology
The Corinne Goldsmith Dickinson Centre for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, USA

Mar Tintoré

Neurology-Neuroimmunology Department
Multiple Sclerosis Centre of Catalonia (Cemcat)
Vall d'Hebron University Hospital
Barcelona, Spain

SCIENTIFIC AGENDA

Welcome & Opening

9.30 G. Comi (Italy) and F.D. Lublin (USA)

Session 1: Understanding Multiple Sclerosis

Chair: G. Comi (Italy)

9.45 **L1 – Updated MS immunology**

A. Bar-Or (USA)

10.05 **L2 – New Diagnostic and prognostic aspects**

M. Tintorè (Spain)

10.25 **L3 – Emerging treatments for relapsing and progressive MS**

G. Comi (Italy)

10.45 **L4 – Remote monitoring in MS**

L. Leocani (Italy)

11.05 **Q&A**

11.25 **Coffee Break and Meet the Experts**

Session 2: Epstein-Barr virus in MS

Chairs: G. Comi (Italy) and H. Lassmann (Austria)

11.45 **L5 – Epidemiology**


A. Ascherio (USA)

12.05 **L6 – Immunopathogenesis**

F. Aloisi (Italy)

12.25 **L7 – Possible interventions**

H. P. Hartung (Germany)

- 
-
- 12.45 **Q&A**
 - 13.05 **Lunch and Meet the Experts**

Session 3: Controversies in Multiple Sclerosis Care

How MS Patients Develop Disability:

Our New Understanding of the Role of Relapses and Progression

Chair: F.D. Lublin, (USA)

- 14.10 **L8 – PIRA - What is it? How Does it Develop?**
L. Kappos (Switzerland)
- 14.30 **L9 – Developing Disability - Reassessing the Spectrum of MS**
F.D. Lublin (USA)
- 14.50 **L10 – Visualizing the Clinical Course of MS Over Time**
S. Krieger (USA)
- 15.10 **L11 – Imaging Progressive Disease**
M. Inglesse (Italy)
- 15.30 **Q&A**

Industry supported session

- 15.50 **Scientific Update on Bruton Tyrosine Kinase Inhibitors to Improve Outcomes for Patients with Multiple Sclerosis**
B.M. Greenberg (USA)
- 16.50 **Strategies to Identify and Manage Spasticity and Related Symptoms in Patients with Multiple Sclerosis**
F.D. Lublin (USA)
- 17.50 **Wrap up**
- 18.00 **End of the day**

Acknowledgment

This educational activity is made possible thanks to an independent medical education grant received by Roche and Sanofi.



sanofi

